Table 3

Age-adjusted 5-year relative survival (RS) for the period 2002-2006 by histologic subtypes and stage for endometrial cancer patients diagnosed in Germany, 1997-2006

Histologic subtypes

Stage

With complete stage information

No stage information

Overall

Localized

Regional

Distant

N (%^b)

RS (SE)

N (%^c)

RS (SE)

N (%^c)

RS (SE)

N (%^c)

RS (SE)

N (%^d)

RS (SE)

Overall

13,456 (100)

81.0 (0.4)

11,634 (86)

91.2 (0.7)

814 (6)

50.5 (3.1)

1,008 (7)

19.8 (2.0)

17,450 (56)

79.5 (0.6)

Adenocarcinoma

12,630 (94)

83.9 (0.4)

11,097 (88)

92.2 (0.7)

736 (6)

50.7 (3.3)

797 (6)

20.0 (2.1)

15,643 (55)

83.3 (0.6)

Adenocarcinoma NOS

4,161 (31)

84.7 (0.7)

3,652 (88)

93.7 (1.1)

221 (5)

288 (7)

18.4 (3.3)

6,266 (60)

83.9 (0.9)

Papillary/clear cell

664 (5)

68.0 (2.2)

523 (79)

83.0 (3.0)

61 (9)

14.0 (4.9)

80 (12)

10.4 (5.0)

807 (55)

70.1 (2.7)

Mucinous/Squamous metaplasia

440 (3)

91.1 (2.2)

388 (88)

96.9 (3.2)

28 (6)

24 (5)

514 (54)

90.8 (2.9)

Adenosquamous

443 (3)

75.0 (2.5)

367 (83)

86.1 (3.7)

35 (8)

41 (9)

414 (54)

72.9 (3.7)

Endometrioid

6,499 (48)

86.0 (0.7)

5,841 (90)

92.9 (1.0)

344 (5)

57.2 (4.9)

314 (5)

22.3 (3.5)

7,151 (52)

84.9 (0.9)

Other adenocarcinoma

423 (3)

68.3 (2.5)

326 (77)

76.8 (4.4)

47 (11)

50 (11)

5.6 (4.5)

491 (54)

71.6 (3.4)

Sarcoma

521 (4)

43.1 (1.8)

350 (67)

61.8 (4.4)

48 (9)

123 (24)

13.7 (4.0)

1,161 (69)

40.1 (2.1)

Abbreviations: NOS = not otherwise specified; RS = point estimates of relative survival (%); SE = standard error (percent units);

^a unstable point estimates of RS (SE > 5 percent units) were not reported;

^b % of histology;

^c % of those with complete stage information;

^d % of cases without stage information.

Chen et al. BMC Cancer 2012 12:128   doi:10.1186/1471-2407-12-128